Aarti PharmaQ1 FY27
Aarti Pharma Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹841P/E: 34.4Market Cap: ₹7.4K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line.
- →Xanthine derivatives expect revenue between INR900 crores to INR1,100 crores this year, with volume ramp-up from 6,000 to 9,500 tonnes in the next couple of years.
- →CDMO/CMO segment aims for 40-50% growth this year, targeting to exceed 25-30% of overall company sales with 57 active projects (37 commercial).
- →Overall company targeting all three segments (Xanthine, API, CDMO) to grow beyond INR1,000 crores each.
- →New product launches in anticancer and antidiabetic drugs expected to contribute to growth.
- →Pricing pressures acknowledged but mitigated via process intensification and cost optimization.
- →Global market share target for Xanthine is 20-25% within 2 years.
Margin guidance
Category 3- →Aarti Pharmalabs targets significant growth across all three segments (Xanthine derivatives, API & Intermediates, CDMO/CMO), each aiming to surpass INR1,000 crores revenue.
- →Q1 FY27 performance showed 42% revenue growth YoY and 40% EBITDA growth YoY, reflecting strong momentum.
- →For API segment, expected recovery and growth supported by debottlenecking on steroids and anticancer blocks, aiming for INR180+ crores quarterly revenue.
- →CDMO/CMO segment is projected to grow 40-50%, contributing about 20-25% of company sales in coming years.
- →EBITDA margin guidance for standalone operations remains between 22%-25% for FY27.
- →Xanthine business revenue expected to stabilize between INR900-1,100 crores this year, despite price fluctuations.
- →Continuous focus on operational efficiency, cost optimization, and new product launches will drive margin improvement and profit growth.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
- →The company is focusing on internal capacity expansions and debottlenecking exercises funded through ongoing capex plans (e.g., INR149 crores for Atali Block 2).
- →Existing expansions and capacity ramp-ups appear to be financed without additional external fundraisings, as indicated by Rashesh Gogri’s comment about not needing further capex beyond current debottlenecking for achieving INR1,000 crores revenue targets.
- →No references were made to approaching capital markets for equity or additional debt in the current communications.
Order book
Yes- →The company is working with 22 customers in the CDMO/CMO segment.
- →There are currently 57 active projects, with 37 in commercial stages and 20 in developmental stages.
- →The CDMO segment is expected to achieve 40-50% growth this year.
- →Visibility exists for multiple dedicated CDMO projects, with 3-4 projects planned for a new dedicated block.
- →The company is confident of reaching INR 1,000 crores revenue in the CDMO/CMO segment.
- →Additionally, the steroid and anticancer API blocks have undergone or are undergoing debottlenecking to enhance capacity.
- →Combined capacity expansions, including Block 5 for steroids and ongoing anticancer expansions, position the company to achieve over INR 1,000 crores in API revenue without additional capex.
Capex plans
Yes- →Completed debottlenecking of steroid block at Unit 4, Tarapur, increasing capacity by 33%.
- →Incremental capacity for Xanthine derivatives commercialized at end of Q1 FY '27; ramp-up expected over next quarters aiming for 80%+ utilization by FY '28.
- →Both phases of Atali Block 1 (440 kL reactor capacity) becoming fully operational in Q2 FY '27, focusing on CDMO/CMO intermediate manufacturing.
- →Announced INR 149 crores capex for Block 2 at Atali with 400+ kL reactor capacity; groundbreaking expected in Q3 FY '27 with 12–15 months completion.
- →Block 2 dedicated to specific CDMO projects; more cost-effective than multipurpose block and a key step toward INR 1,000 crores CDMO/CMO revenue goal.
- →No additional capex required for API business to achieve INR 1,000 crores revenue post debottlenecking and expansions.
- →Civil work planned to support future capacity ramp-up by 200 kL at Vapi site within 6–9 months.
How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Aarti Pharma
Rev 2Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Aarti Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.